CatalystWireBeta

Ethics submission for Ox-1 Phase 1 study

In brief · summary, not quotable

TheraCryf submits Phase 1 ethics application for Ox-1 receptor antagonist to Australian HREC.

vs expectations: in line

Full announcement

Select text to share a quote on X · sign in to keep highlights & notes in your TCF notes

TheraCryf plc, the biotech company developing new medicines for addiction and other neuropsychiatric disorders such as fatigue, announces that it has submitted an application to the Bellberry Human Research Ethics Committee ("HREC") in Australia for a first-in-human Phase 1 study of its lead orexin-1 (Ox-1) receptor antagonist.

The application was submitted on behalf of the Company’s wholly owned subsidiary, TheraCryf Australia Pty Ltd, in line with the November 2026 timetable previously announced. The submission follows completion of the preclinical data package announced on 19 October 2026, including the final reporting of the 28-day regulatory toxicology studies in two species.

Following anticipated HREC approval, the Company will lodge a Clinical Trial Notification (CTN) with Australia’s Therapeutic Goods Administration (TGA). The Company continues to target the necessary approvals by the turn of this calendar year.

Australia provides an efficient and well-established pathway for early-stage clinical studies, which was a key factor in the Company's decision to conduct its Phase 1 programme there.

Dr Huw Jones, Chief Executive Officer of TheraCryf, commented:

“Today’s submission to the ethics committee in Australia is the culmination of a huge body of work by our internal team together with our expert consultants and research partners. It was made exactly in line with our guidance on timing. Securing the approvals to progress to human volunteers, which we anticipate around the turn of this year, would be a major inflection point for our addiction programme and pave the way for us to become a clinical-stage neuropsychiatry company.

“Congratulations to our extended team for delivering yet again. We eagerly anticipate the approval from the Australian authorities and the potential this has to enhance the value of both the programme and the company.

Cleaned text: letterheads, contacts and legal notices removed. Official copy: FCA National Storage Mechanism ↗ · Company filings. Not investment advice.

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note